Platelet Glycoprotein – GPIIb/IIIa Antibody

Affinity Biologicals, Inc. manufactures a Platelet Glycoprotein – GPIIb/IIIa Antibody which can be found in the listing below.   Further information about our Platelet Glycoprotein – GPIIb/IIIa polyclonal antibody is available by following the links below.  Our Platelet Glycoprotein – GPIIb/IIIa Antibody’s immunogen is prepared from purified glycoprotein IIb/IIIa complex (GPIIb/IIIa) prepared from platelets and is specific for GPIIa/IIIb as demonstrated by immunoelectrophoresis and ELISA. Affinity’s Platelet Glycoprotein – GPIIb/IIIa.  Antibodies are manufactured for use in research applications.

GPIIb/IIIa, HumanHostCatalogue No.Size
Purified IgGSheepSA2B3A-IG10mg vial

Listing of Platelet Glycoprotein – GPIIb/IIIa Antibody

Description of Platelet Glycoprotein – GPIIb/IIIa

Glycoprotein (GP) IIb/IIIa (αIIbβ3) serves as the receptor on platelets that binds plasma-borne adhesive proteins, such as fibrinogen and von Willebrand factor (vWF), to permit platelet aggregation.1 Aggregation is mediated by this pathway, irrespective of the agonist that stimulates platelets and irrespective of the stimulus-response–coupling pathway that is used to activate GP IIb/IIIa to aggregate platelets. Agents that block this final common pathway by blocking the binding of adhesive proteins to GP IIb-IIIa, termed GP IIb/IIIa antagonists, are currently considered the most powerful specific inhibitors of platelet participation in acute thrombosis.2

References and Reviews

  1. Phillips DR, Charo IF, Scarborough RM. GP IIb/IIIa. The responsive integrin. Cell. 1991;65:359–362.
  2. Topol EJ. Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence. Circulation. 1998;97:211–218.